Published in Invest Ophthalmol Vis Sci on May 01, 2007
Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther (2009) 1.34
Mediators of ocular angiogenesis. J Genet (2009) 1.17
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res (2013) 1.06
Gene delivery to cornea. Brain Res Bull (2009) 1.01
Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci (2009) 1.00
Strategies for local gene therapy of corneal allograft rejection. Middle East Afr J Ophthalmol (2013) 0.94
BMP7 gene transfer via gold nanoparticles into stroma inhibits corneal fibrosis in vivo. PLoS One (2013) 0.92
Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis (2007) 0.92
Gene therapy in the cornea: 2005--present. Prog Retin Eye Res (2011) 0.92
Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano (2013) 0.91
Horizons in therapy for corneal angiogenesis. Ophthalmology (2011) 0.90
Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS One (2011) 0.90
Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci (2012) 0.88
Corneal gene therapy: basic science and translational perspective. Ocul Surf (2013) 0.87
Electrically assisted delivery of macromolecules into the corneal epithelium. Exp Eye Res (2009) 0.87
Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone. Invest Ophthalmol Vis Sci (2012) 0.85
Clinical correlates of common corneal neovascular diseases: a literature review. Int J Ophthalmol (2015) 0.82
Emerging techniques to treat corneal neovascularisation. Eye (Lond) (2011) 0.82
AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization. Mol Ther (2014) 0.82
Attenuation of corneal myofibroblast development through nanoparticle-mediated soluble transforming growth factor-β type II receptor (sTGFβRII) gene transfer. Mol Vis (2012) 0.80
Ocular drug delivery: a clue from nanotechnology. Front Pharmacol (2012) 0.80
Nanotechnology in corneal neovascularization therapy--a review. J Ocul Pharmacol Ther (2013) 0.79
Gene delivery nanoparticles fabricated by supercritical fluid extraction of emulsions. Int J Pharm (2009) 0.79
Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment. Mol Ther (2017) 0.77
Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics. Indian J Pharm Sci (2010) 0.76
Targeting herpetic keratitis by gene therapy. J Ophthalmol (2012) 0.76
The Effect of Silica Nanoparticles on Human Corneal Epithelial Cells. Sci Rep (2016) 0.75
Systematic assessment of microneedle injection into the mouse cornea. Eur J Med Res (2012) 0.75
An Evaluation of the in vivo Safety of Nonporous Silica Nanoparticles: Ocular Topical Administration versus Oral Administration. Sci Rep (2017) 0.75
[Use of nanoparticles in ophthalomology]. Ophthalmologe (2011) 0.75
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med (2003) 6.61
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol (2003) 5.22
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 3.17
DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell (2012) 2.81
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med (2009) 2.39
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
Concern Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol (2011) 1.69
Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases. Drug Deliv Transl Res (2011) 1.58
Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity. Blood (2013) 1.56
Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano (2012) 1.56
Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci (2006) 1.52
Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos (2011) 1.48
Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res (2008) 1.36
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A (2009) 1.36
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest (2006) 1.36
Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 1.34
Periocular routes for retinal drug delivery. Expert Opin Drug Deliv (2004) 1.31
Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol (2005) 1.30
Cancer education for Community Health Aides/Practitioners (CHA/Ps) in Alaska assessing comfort with cancer. J Cancer Educ (2005) 1.29
Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol (2005) 1.28
Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci (2008) 1.25
Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol (2006) 1.22
Genetic heterogeneity of KID syndrome: identification of a Cx30 gene (GJB6) mutation in a patient with KID syndrome and congenital atrichia. J Invest Dermatol (2004) 1.21
Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol (2003) 1.19
Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci (2006) 1.18
Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull (2009) 1.18
Mediators of ocular angiogenesis. J Genet (2009) 1.17
Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release (2002) 1.17
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res (2004) 1.15
Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci (2010) 1.15
Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis (2008) 1.15
Retracted Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J Pharmacol Exp Ther (2009) 1.14
Physician and staff perceptions of barriers to colorectal cancer screening in Appalachian Kentucky. Cancer Control (2007) 1.13
Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci (2005) 1.13
A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res (2002) 1.10
Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther (2011) 1.09
Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes (2009) 1.08
Corneal stroma PDGF blockade and myofibroblast development. Exp Eye Res (2008) 1.08
Anterior chamber intraocular lens, sutured posterior chamber intraocular lens, or glued intraocular lens: where do we stand? Curr Opin Ophthalmol (2012) 1.07
Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Release (2002) 1.06
Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife (2013) 1.06
Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res (2008) 1.05
Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol (2009) 1.05
Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS One (2012) 1.05
Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond) (2010) 1.04
Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation. PLoS One (2011) 1.01
Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS PharmSciTech (2002) 1.01
Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci (2009) 1.00
Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One (2012) 1.00
Retracted Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models. Invest Ophthalmol Vis Sci (2011) 1.00
ERK1/2 activation is a therapeutic target in age-related macular degeneration. Proc Natl Acad Sci U S A (2012) 0.99
Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci (2008) 0.98
Whirlin replacement restores the formation of the USH2 protein complex in whirlin knockout photoreceptors. Invest Ophthalmol Vis Sci (2011) 0.97
Luteinizing hormone-releasing hormone agonist and transferrin functionalizations enhance nanoparticle delivery in a novel bovine ex vivo eye model. Mol Vis (2006) 0.96
Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. Eur J Pharmacol (2002) 0.95
Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol (2004) 0.94
Cassette analysis of eight beta-blockers in bovine eye sclera, choroid-RPE, retina, and vitreous by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.94
Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea (2007) 0.93
Flt-1 intraceptor induces the unfolded protein response, apoptotic factors, and regression of murine injury-induced corneal neovascularization. Invest Ophthalmol Vis Sci (2006) 0.93
The capsule drug device: novel approach for drug delivery to the eye. Vision Res (2009) 0.93
Budesonide reduces multidrug resistance-associated protein 1 expression in an airway epithelial cell line (Calu-1). Eur J Pharmacol (2002) 0.93
Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci (2014) 0.93
Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes. Exp Eye Res (2012) 0.92
Human serum albumin nanoparticles for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vis (2007) 0.92
Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res (2009) 0.92
Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J Clin Invest (2014) 0.92
Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). J Ocul Pharmacol Ther (2009) 0.91
Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs. Nanomedicine (2011) 0.91
Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes. Mol Vis (2013) 0.91
Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano (2013) 0.91
Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein. J Mol Graph Model (2007) 0.90
Horizons in therapy for corneal angiogenesis. Ophthalmology (2011) 0.90
Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol (2013) 0.90
Quality of vision and patient satisfaction after LASIK. Curr Opin Ophthalmol (2004) 0.90
Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm Res (2004) 0.89
Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther (2011) 0.89
Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR). FASEB J (2012) 0.89
Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J (2009) 0.88
Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol (2003) 0.88
Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS One (2012) 0.88
Nanoparticle-mediated delivery of shRNA.VEGF-a plasmids regresses corneal neovascularization. Invest Ophthalmol Vis Sci (2012) 0.88